Atomwise
Matthew Merkley serves as Sr. Director at Atomwise since December 2022, following a tenure as Associate Director of Program Management at Bolt Biotherapeutics, Inc., where responsibilities included overseeing the BDC-2034 program’s IND and engaging with the FDA for timely submission. Prior experience includes pivotal roles at Gilead Sciences as Senior Project Manager and Clinical Pharmacology Project Manager, contributing to global regulatory filings for key products like Veklury and Biktarvy, and managing clinical pharmacology activities. Matthew's career began in research roles, including a Research Assistant position at Gilead and clinical research roles at various institutions. Educational credentials include an MA in Medical Science from Boston University School of Medicine and a Bachelor of Science in Biochemistry/Molecular Biology from the University of California, Davis.
This person is not in any offices
Atomwise
4 followers
Atomwise patented the first deep learning technology for structure-based small molecule drug discovery. This AI technology harnesses millions of data points and thousands of protein structures to solve problems that a human chemist would take many lifetimes to solve. They've partnered with some of the world’s largest pharmaceutical and agrochemical companies, and with more than 50 leading academic institutions and hospitals, to tackle the challenges of discovering and developing better drugs and chemicals.